Featured from left to right are McGlinn Cancer Institute team members: Gary Xiao, MD, General Surgery; Michael Brown, MD, Medical Director, McGlinn Cancer Institute at Reading Hospital; Peter Bamberger, MD, General Surgery.
Featured from left to right are McGlinn Cancer Institute team members: Gary Xiao, MD, General Surgery; Michael Brown, MD, Medical Director, McGlinn Cancer Institute at Reading Hospital; Peter Bamberger, MD, General Surgery.

With leading-edge treatment focusing on a multidisciplinary approach to care for the “whole patient,” McGlinn Cancer Institute (MCI) at Reading Hospital has established itself as a premiere healthcare resource for cancer patients in the Berks County region. MCI continues to receive national accolades, most recently, being named an NPF Pancreatic Cancer Center of Excellence by the National Pancreas Foundation.

The NPF Center of Excellence designation is awarded to institutions that model a multidisciplinary approach to pancreatic disease treatment by taking the "whole person" into consideration. A rigorous audit then reviews an institution’s commitment to the best possible outcomes and improved quality of life.

“This is a strong demonstration that our team members are committed to providing the highest-quality and most innovative care possible to our community,” said Charles F. Barbera, MD, Reading Hospital president and CEO. “I thank our team for their diligent work and dedication to receiving this prestigious recognition.”

An approved NPF Center must meet criteria and standards developed by a task force comprised of subject matter experts and patient advocates. The guidelines include having the requisite specialty physicians such as gastroenterologists, pancreatic surgeons, and interventional radiologists. Additionally, patient-oriented services offering pain management, psychosocial support, nutritional guidance, and more are also essential. Designated centers also seek to advance research.

“I am very proud of this achievement and of our team's continued effort to deliver excellent patient care,” said Michael Brown, MD, Medical Director, McGlinn Cancer Institute at Reading Hospital. “This acknowledgment demonstrates we are proficient, and equipped to meet the needs of individuals who suffer from pancreas disease.”

 

About Reading Hospital

Reading Hospital is the flagship, Magnet Recognized, acute care hospital of Tower Health. Located in West Reading, Pa., Reading Hospital is a 697-bed hospital that is home to many top-tier specialty care centers, including Reading HealthPlex, McGlinn Cancer Institute, Miller Regional Heart Center, Emergency Department, Level I Trauma Center and Beginnings Maternity Center, which houses the region's only Level III Neonatal Intensive Care Unit (NICU). With more than 1,000 physicians, specialists, and advanced practice providers across 49 locations, Reading Hospital has been recognized for its quality outcomes and clinical expertise across services lines. It is listed as one of America's 100 Best Hospitals for four consecutive years (and moving up to America’s 50 Best Hospitals in 2022) and received a 5-Star Rating from CMS two years in a row. For more information, visit towerhealth.org.